Karo Bio split 'still on' despite Pfizer discovery deal
This article was originally published in Scrip
Executive Summary
Karo Bio's share price received a welcome boon following news that it has managed to secure a discovery and development alliance with Pfizer for its early-stage small molecule RORgamma modulator programme for the treatment of autoimmune diseases.